This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jensen: A Pair of Healthy Generic Drug Makers

Overall prescription drug spending in the U.S. rose 1%, year over year, in May, its strongest month of growth of 2012. Generic drugs posted a much better growth rate of 5% offsetting the 16% decline in branded drugs. I like the generic drug sector at current valuations and have a couple in my portfolio. Generics have several long-term tailwinds in their favor:

A. The aging of the population in developed countries.

B. Huge new markets coming online in the emerging economies.

C. The constraints in Western government's budgets, providing a large incentive to move to generics paid for by government programs.

D. A significant amount of blockbuster branded drugs coming off patent over the next several years.

These secular trends have led Credit Suisse to project generics will account for 89% of all drug prescriptions in 2021 from 77% today. Here are two generic drug makers that look good right now based on valuation and long-term prospects.

Mylan (MYL - Get Report) is a worldwide generic (91% of total revenues) and branded drug maker with a market cap of just over $9 billion.

Four reasons MYL delivers good value at $21 a share:

  • The stock is selling at the bottom of its five-year valuation range based on P/B, P/E and P/CF.
  • The company has pursued strategic acquisitions that have allowed it to increase revenues at an annual clip north of 22% over the past five years. It has several key products including an epinephrine auto-injector with more than 95% market share in the U.S. In addition, 30% of worldwide HIV patients use a Mylan product.
  • Mylan has done a solid job of reducing the debt incurred for these acquisitions over the past few years and has grown its adjusted EBITDA at an average 17.5% yearly clip over the preceding four years.
  • The company has exceeded earnings estimates each of the last four quarters and consensus earnings estimates for FY2012 and FY2013 have ticked up over the last two months. MYL sells for a forward PE of under 8, a significant discount to its five-year average (14.4).

Teva Pharmaceuticals (TEVA - Get Report) is the largest generic drug maker in the world and is based in Israel.

Four reasons TEVA is a solid long-term value pick for patient investors at $38 a share:

  • The company has been hit hard by worries about the expiration of its best-selling drug, Copaxone, as well as recently reduced guidance. However, as it is trading at just 6.5 forward earnings, the bad news appears fully priced into the stock.
  • The company has a well-respected new CEO, who should serve as a long-term catalyst and change agent for the company and the stock. Easing of the situation in Iran also should reduce the "Israel" discount hanging over TEVA as well.
  • The stock sells at the very bottom of its five-year valuation range based on P/E, P/S, P/CF and P/B. TEVA also yields 2.1%.
  • The median analysts' price target is $51 a share for the 20 analysts who cover Teva Pharmaceuticals. The stock also appears to have technical support just under current price levels.

At the time of publication, Jensen was long MYL and TEVA.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Our Tweets

Partners Compare Online Brokers

Top Rated Stocks Top Rated Funds Top Rated ETFs